Menopause Hormone Therapy: Why Timing Changes the Whole Answer

A woman of fifty-one arrives with a short list: a year without one unbroken night of sleep, hot flushes that wake her again and again, concentration that has fallen apart at work, dryness that has made sex painful. She has already asked about menopause hormone therapy, and received the answer nearly every woman receives in one version or another: it raises breast cancer risk, better to wait it out. That answer is neither malicious nor invented. It rests on one reading of one result from 2002 — a reading the field itself has since largely corrected, without the correction ever reaching the waiting room.

The product of that half-finished correction is a generation of women with treatable symptoms being told to endure them. This article is about that gap: what the WHI measured and in whom, why the age at which treatment starts changes the whole answer, and what hormone therapy treats — and does not.

What the WHI measured, and in whom

The Women's Health Initiative was built to answer one question: does hormone therapy prevent chronic disease — coronary heart disease above all — in postmenopausal women. It was never a study about hot flushes. The women recruited, accordingly, were not women at the peak of their symptoms but considerably older ones: the average age at enrolment was in the early sixties, a decade or more past the final menstrual period for many of them. In 2002 the combined oestrogen-progestogen arm was stopped early, and the headline that circled the world was that risks outweighed benefits.

Use of hormone therapy collapsed within months, in Israel as everywhere else. The finding was not wrong for the population studied. The error was the generalisation: a conclusion measured in a woman in her sixties, more than a decade past her last period, was transferred almost automatically to a woman of fifty-one who has only just stopped sleeping. Two different physiologies — and the twenty years since have shown their benefit-risk balance differs too.

The timing hypothesis — why "is menopause hormone therapy safe" is an incomplete question

Later analyses of the WHI, stratified by age and by time since the final menstrual period, showed a different picture in the younger group. From this came the timing hypothesis: in a woman starting treatment roughly within a decade of her last period and under the age of sixty, the balance of benefit and risk is far more favourable than in a woman starting fifteen years after it. The accepted explanation is the state of the arteries: oestrogen given to relatively young vessels behaves differently from oestrogen given to vessels already carrying established atherosclerotic plaque.

Honesty requires saying how far the evidence reaches. The hypothesis rests on subgroup analyses and several dedicated studies, most of which measured surrogate markers such as arterial wall thickness rather than cardiac events, and it now underpins the mainstream guidelines. What is missing is a large trial with clinical outcomes designed in advance to answer it. Well-founded enough to change a clinical decision; not well-founded enough to start treatment in a woman without symptoms on the basis of her age.

"Is hormone therapy safe" is a question without an age attached, and so it has no answer. Attach an age and a time since the last period, and it becomes a question that can be answered.

What the treatment genuinely addresses

The indications are well defined, and worth knowing precisely — mostly so you can recognise when someone is offering something beyond them.

• Vasomotor symptoms. Hot flushes and night sweats. Systemic hormone therapy is the most effective treatment available for them today. Non-hormonal alternatives exist for women who are not candidates, and are generally less effective.
• The sleep disruption they cause. When the awakenings are driven by night sweats, treating the symptom improves the sleep. Poor sleep from another cause will not improve from here.
• Genitourinary symptoms. Dryness, pain with intercourse, urinary urgency and recurrent urinary infections. Low-dose local vaginal oestrogen, whose systemic absorption is negligible, is a simple treatment and used far less than it should be — including in women who are not candidates for systemic therapy.
• Bone protection. Treatment slows the accelerated bone loss of the first years after menopause and reduces osteoporotic fractures — a genuine secondary benefit in a symptomatic woman who is also at fracture risk.

And what it is not

Hormone therapy is not recommended as a strategy for preventing chronic disease in a woman without symptoms. It is not an anti-ageing treatment, does not replace lipid or blood pressure management, and is no substitute for resistance training. Anyone selling it as a component of a longevity programme is selling more than the evidence supports — true even when they happen to be right about a woman who has an indication anyway.

A separate note on compounded "bioidentical" preparations mixed to order in a pharmacy: no evidence shows them safer or more effective than regulated products, their actual dosing is less consistent, and some — pellet implants and custom creams especially — are marketed with promises that have no research behind them. Regulated preparations already contain hormones chemically identical to those the body produces.

Perimenopause — where most of the confusion lives

The transition begins years before the final menstrual period, and this is exactly where women get the worst answers. Periods still arrive, sometimes perfectly regularly, and yet sleep shortens, mood swings, bleeding turns heavier or cycles shorter, and hot flushes come and go. The diagnosis is clinical: in a woman over forty-five with typical symptoms, no blood test is needed to make it.

FSH is a principal source of confusion. In perimenopause it varies enormously cycle to cycle, and a normal result rules out nothing. "They checked my hormones and everything was fine" is among the commonest sentences that lead to two years of unnecessary waiting. A panel is genuinely useful when other explanations for the same symptoms need excluding — a thyroid disorder or anaemia, for instance — or when symptoms appear before forty-five, in which case the work-up is different.

What shifts at menopause, and what is worth measuring again

Even a woman who ultimately takes nothing goes through a measurable metabolic shift in these years. It is a good moment to establish a fresh baseline rather than assume what was measured at forty still holds.

None of these measures depends on the hormone therapy decision; they hold whichever way it goes. A rise in ApoB in these years is treated like any rise in ApoB; snoring and fatigue are evaluated the way suspected sleep apnoea is evaluated. Some of these tests are covered by the national health basket or by supplementary insurance (bituach mashlim) to an extent that varies between the health funds (kupot holim), so it is worth checking in advance. Anyone who wants it done at once and in an organised way can go through a comprehensive assessment — but it can certainly be done through a family physician too.

The risks, neither softened nor inflated

The risks are real, moderate, and dependent on the preparation, the route, the age at which treatment starts and its duration. Breast cancer risk is associated chiefly with combined oestrogen-progestogen therapy; the absolute increase is small, and becomes relevant mainly after several years of use. In the oestrogen-only arm, given to women who had undergone hysterectomy, that signal did not appear. Clotting and venous thromboembolism risk comes largely from oral oestrogen, whereas a patch or gel bypasses first-pass liver metabolism and appears safer in this respect — a comparison that rests mainly on observational data. Oral therapy also carries a small increase in stroke risk, chiefly in women starting at an older age. Which is why "which preparation, by which route" is no technical footnote.

Separately from the treatment decision, it is worth being up to date with breast screening for your age. The national programme in Israel invites women for mammography every two years between fifty and seventy-four, and screening starts earlier and looks different for women with a significant family history or a known genetic risk; exact eligibility is worth checking with your health fund.

There are also situations in which the answer is a clear no, or genuinely complicated: prior breast cancer, a previous clotting event, active liver disease, unexplained vaginal bleeding, a previous stroke. That decision belongs to a gynaecologist who knows menopause well — not to a longevity physician and not to an article on the internet. Dedicated menopause clinics do operate in Israel, in hospitals and in some health fund settings. It is worth finding out what is available locally and asking for that referral explicitly, rather than settling for whichever appointment comes up soonest.

The right question is not "is it safe" but "am I a candidate"

That reframing is the one practical change this article asks for. Instead of a general question with no answer, arrive at the appointment with the details that make it a personal one:

• When the last period was, or how long the cycle has been irregular. That number defines the window.
• Which symptoms actually interfere, and how severely — awakenings a night, flushes a day, what is suffering at work. A precise description is worth more than any blood test.
• Family history of breast or ovarian cancer, any clotting event, migraine with aura, uncontrolled blood pressure or lipids.
• Genitourinary symptoms, raised separately. Local oestrogen is considered even when systemic therapy is off the table.
• The preparation and the route, not just "yes or no": oral versus patch or gel, and how the uterus is protected in a woman who has not had a hysterectomy.
• When the decision gets revisited — this treatment is reviewed yearly, not set for life.

A woman with significant symptoms, within a decade of her final period, without a contraindication, is a reasonable candidate for a serious conversation — not a case to be waited out. A woman without symptoms seeking protection against ageing is not a candidate, even if someone will sell it to her. Between those poles sit many cases that need a proper discussion, which is entirely fine — provided it rests on what is known today, not on a journalistic summary from 2002. Anyone wanting the whole metabolic picture of these years put in order in one place is welcome to book a consultation.